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Abstract
The aim of this study was to measure the radiation exposure rate from differentiated thy-
roid carcinoma (DTC) patients who had received iodine-131 (131I) treatment, and to evalu-
ate hospital discharge planning in relation to three different sets of regulations. We stud-
ied 100 patients, 78 females and 22 males, aged 13 to 79 years (mean 44.40±15.83 years) 
with DTC, in three Groups who were treated with 3.7, 5.5 or 7.4GBq of 131I, respectively. 
The external whole-body dose rates following oral administration of 131I were measured 
after each one of the first three hospitalization days. A multivariant linear analysis was 
performed, considering exposure rates as dependent variables to the administered dose 
for treatment, age, gender, regional and/or distant metastases, thyroglobulin (Tg), an-
tibodies to Tg and thyroid remnant in the three dose groups. We found that the expo-
sure rates after each of the three first days of hospitalization were 30, 50 and 70µSvh-1 
at 1m. All our DTC patients had an acceptable dose rate on days 2 and 3 that allowed 
their hospital discharge. After only 1 day of hospitalization, just 3/11 cases showed not 
permissible exposure rates above 70µSvh-1. In conclusion, it is the opinion of the authors 
that after measuring the exposure rates, most treated, DTC patients could be discharged 
after only one day of hospitalization, even some of those treated with high doses of 131I 
(7.4GBq). Patients, who received the higher doses of 131I, should not be released before 
their individual exposure rate is measured. 
Introduction
D ifferentiated thyroid carcinomas (DTC) are the most frequent malignan-cies of the endocrine system, with an annual incidence in 2005 in USA, of 14.9 and 5.1 per 100,000 among women and men, respectively [1-3]. 
Radioactive iodine-131 (RAI) has been routinely used for the ablation of DTC 
remnant after total thyroidectomy, for more than 50 years [1]. 
Radiation hazard, a significant safety issue, consists of both external radiation 
hazard, through radiation emitted from the patients, and internal radiation haz-
ard, through radioactive substances from the patients that could be ingested 
and contaminate others [1, 2].
Precautions and safety criteria are necessary to restrict the radiation expo-
sure to the public, to the patients’ family members and also to the staff treat-
ing these patients [3]. These safety criteria vary between countries, mainly 
due to various socio-economic and cultural factors. A number of guidelines 
and regulations, mostly based on the administered doses, have been estab-
lished, in order to decide when these patients shall be discharged from the 
hospital [4, 5]. Usually DTC patients receiving high-dose 131I treatment are hos-
pitalized until the remaining radioactivity in their body is less than 1110MBq, 
or the measured exposure rate is less than 5mR/h at a distance of 1m from the 
patient [4]. The US Nuclear Regulatory Commission regulatory guide (No. 8.39) 
allows the release of DTC patients based on a measured dose rate of 7mR/h 
at 1m [6]. Exposure rate and discharge time, based on certain parameters and 
mathematical equations have been presented in a number of studies [4, 5]. 
Many other researchers have also proposed related guidelines [6-10] to which 
all do not agree.
The objective of this study was to measure the radiation exposure rate at 1m 
from three DTC Groups of patients who had received three different doses of 131I 
for thyroid remnant ablation treatment, in order to decide upon the day of hos-
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much of the variance in the dependent variable is explained 
by the model was expressed. Likewise, repeated measure-
ments were assessed using ANOVA. A statistical P value of 
less than 0.05 was considered significant. Statistical package 
for the social sciences (SPSS) for Windows software package 
(Release 18, SPSS Inc., Chicago, Illinois) was used for statisti-
cal analysis. 
Results
We compared age, sex, exposure rate on days 1-3, TSH, Tg 
and anti-Tg, in the three groups studied (Table 1). In Table 2, 
we describe multiple linear regression analysis for the corre-
lation between exposure rates at 1m (as dependent variable) 
with age, gender, administered 131I activity (as independent 
variables) on days 1-3 after 131I administration. In Table 3, we 
pital discharge [11]. Specific parameters that may alter the 
exposure rate have also been studied.
Material and methods
Study design
One hundred DTC patients who had been treated with 131I in 
our Nuclear Medicine Department between 2010 and 2011 
were enrolled in this study. All patients had a history of a to-
tal, or near total, thyroidectomy [11]. Thyroid remnant was 
poorly detected on the whole body scan (WBS).
 The 131I dose administered was based on several factors, in-
cluding regional or distal metastases, levels of TSH and Tg.
 All patients were on a low-iodine diet and had not taken 
any containing iodine drugs, prior to the diagnostic WBS. Di-
agnostic WBS was done 48h after the oral administration of 
74-185MBq 131I. Serum levels of thyroid stimulating hormone 
(TSH) (normal value, 0.3-4mIU) and anti thyroglobulin (anti-
Tg) antibodies (normal value, <100ng·ml-1) were measured 
by the immunoradiometric assay (RADIM, Italy). Thyroglobu-
lin was measured by the radioimmunoassay method (CIS Bio 
International, France). All patients were duly informed about 
the treatment procedure and gave their written consent. 
The study complied with the Helsinki declaration and was 
approved by the Institutional Ethics Committee of Shahid 
Beheshti University of Medical Sciences.
We studied the following information for every patient: 
age, gender, tumor histology, regional or distant metastas-
es, TSH, Tg and anti-Tg antibodies.
Patients were divided into three groups according to the 
administered activity: 3.7GBq, 5.55GBq and 7.4GBq. The 
whole body exposure rates were measured at a distance of 
1m by a radiation-detector survey meter with an ionization 
chamber counter (Geiger-Müller GM X5C plus, Graetz, Ger-
many) calibrated in µSv/h. For some patients for better as-
sessment of the hospital discharge day, radiation exposure 
rates at a distance of 2m were also measured. The maximum 
dose rate from the neck area and from the upper trunk por-
tion of every DTC patient were measured. All dose rate meas-
urements were performed after patients had emptied their 
urine bladder and background was subtracted. The post-
treatment dosimetry was performed on each one of the 
three first days following the administration of 131I at a dis-
tance of 1m and for some patients at 2m on the first, second 
and on the third day of hospitalization (D1, 2, 3 at 1, 2m). 
Our patients were 78 female and 22 male, ranging in age 
from 13 to 79 years (mean 44.40±15.83 years). Eighty nine 
patients had papillary thyroid cancer (PTC), 9 had follicular 
thyroid cancer (FTC) and 2 cases had Hűrtle cell carcinoma. 
Thirty patients received 3.7GBq; 59 received 5.55GBq and 
11 received 7.4GBq, Groups I, II and III, respectively. The ex-
posure rates on different days are stated in Figure 1. 
Statistical analysis
All data were expressed as the mean±SD, with ranges given 
when appropriate. Continuous variables were compared by 
the unpaired t test, and categorical variables were compared 
by x2 analysis. The relationship among clinical and labora-
tory factors variables with exposure rates was evaluated 
with multivariate linear regression model. For each model 
β, coefficient of each independent variables and ρ, P value 
were acquired. In addition, R2 value which is indicated how 
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Table 1. Comparison age, exposure rate at 1m on days 1-3, 
TSH, Tg and anti-Tg antibodies, in the  three groups studied
  Variable Value (m±SD)  P value
   Group I  
»    II 
»   III
       Total 
         41.5 ± 12.86
   44.34 ± 16.38
52.64 ± 18.58
44.40± 15.83  years
0.13
Group I      
»     II 
»    III
       Total 
D1-1m
158.00 ± 93.39
162.88 ± 74.51
            278.18 ± 170.10
174.10 ± 100.43 µSvh-1
0.00
Group I     
»  II 
  »  III         
Total
D2-1m
33.27 ± 18.52
50.64 ± 45.14
50.91 ± 22.86
45.46 ± 3.92 µSvh-1
0.10
Group I 
»    II
»   III
Total
D3-1m   
*9(3-25) 
*14.50(3-75)
*18.50(7-35)
   *13(8-19.50) µSvh-1
0.10
Group  I
II »   
  »   III
      Total
TSH      
61.75 ± 35.36
66.15 ± 42.07
44.18 ± 23.47
62.30 ±38.67 mIU·l-1
0.22
Group I
»    II
»   III
Total
Tg          
*1.90(2-88)
*13.40(2-1900)
*270.20(1.6-1000)
*15.20(2.25-60.67)ng·mL-1
0.07
      Group I
»   II
»  III
Total
    Anti-Tg 
*68(2-915)
*19(2-3000)
*19.68(5-51.7)
*25(12.42-67.50)ng·mL-1
0.75
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compared the number of patients having different exposure 
rates on days 1-3 at 1m in the three dose groups studied. The 
exposure rates on the first 3 days are seen in Figure 1.
                             (mSv/h)                       (mSv/h)                       (mSv/h)
Figure 1. 95% confidence interval of the mean dose rate of the patients at 1m 
on each of the first three days post 131I administration.
Discussion
Radiation safety hazard is the major issue following 131I treat-
ment of DTC patients and exposure rate from these patients 
reflects this issue [5, 12-15].
Since functional metastatic lesions cause slower RAI clear-
ance from the body, accumulation of RAI in RAI-avid meta-
static lesions increases whole-body exposure rate [1]. In our 
analysis, although radiation exposure was significantly corre-
lated with distant metastases on days 1 and 2, it did not have 
a significant relationship on day 3. Our data demonstrated a 
borderline correlation between age and exposure rate, 3 days 
after admission. This may indicate a correlation between age 
and a lower clearance of RAI. However, a dosimetry survey af-
ter RAI treatment for older patients may be necessary. 
Table 2. Multiple linear regression analysis of the correla-
tion between exposure rates at 1m (as dependent variable) 
with age, gender and administered 131I activity (as independ-
ent variables) on  days 1-3 following 131I administration.
Variable Exposure rate 
β ρ R2
Day 1 0.239
Age        0.134 0.38
Gender     0.47 *0.00
Activity adm. 0.225 0.34
Distant  mets 0.65 *0.00
Day 2 0.176
Age        0.27 0.09
Gender      0.19 0.17
Activity adm. 0.52 *0.04
Distant mets 0.52 *0.02
Day 3 0.166
 Age        0.30 0.06
Gender     0.07 0.62
Activity adm. 0.25 0.31
Distant mets 0.11 0.61
Mets: metastases, adm: administered, β: Coefficient of each in-
dependent variables, ρ: P value, R2: This indicates how much 
of the variance in the dependent variable is explained by the 
model.
Table 3. Comparison of the number of patients having different exposure rates on days 1-3 in the three dose groups studied
Variable
Exposure 
rate <30 
µSvh-1
Exposure 
rate >30 
µSvh-1
P value
Exposure 
rate <50 
µSvh-1
Exposure 
rate >50 
µSvh-1
P value
Exposure 
rate <70 
µSvh-1
Exposure 
rate >70 
µSvh-1
P value
D1-1m
Group I
      »    II
»   III
Total
0
0
0
0
30
59
11
100
-
2
0
0
2
28
59
11
98
0.09
5
2
0
7
25
57
11
93
0.04
D2-1m
Group I
      »   II
   »  III
Total
20
13
3
36
10
46
  8
64
0.00
25
47
  8
80
  5
12
  3
20 0.75
28
52
  9
89
2
7
2
11
0.54
D3-1m
Group I
      »   II
   »  III
Total
29
54
9
92
1
5
2
8
0.29
30
57
11
98
0
2
0
2 0.49
30
57
11
98
0
2
0
2
0.49
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In addition, the multivariate linear analyses for the param-
eters in different days showed a significant relation between 
exposure rate and administered activity on day 2. This rela-
tion in the other two days was also positive but when adjust-
ed for the other clinical and laboratory parameters failed. 
The average exposure rate may be altered  due to patients’ 
prescribed  activities, age groups, gender, weight, the vol-
ume of functioning thyroid, the volume of metastatic tissue, 
and the rate of renal and bowel excretion [1].  
Discharging most of the patients after 1 day of hospitaliza-
tion with instructions about how to keep the dose emitted 
to other persons “as low as reasonably possible” has many 
advantages, besides fewer hospital stays, that is to: reduce 
the radiation exposure of hospital personnel, lower health 
care charges, provide psychological advantages for patients 
and families, and improve the quality of life of patients. Stud-
ies of family members of DTC patients undergoing outpa-
tient 131I treatment for DTC have mentioned that provided 
the appropriate instructions decreases radiation exposure 
of primary caregivers to <5mSv [12-15]. 
In 1997 the Nuclear Regulatory Commission (NRC) revised 
the regulations regarding hospital discharge of DTC patients 
following treatment with 131I [16]. The previous patient- re-
lease criteria was the retained activity (<1,110MBq) or an ex-
posure dose rate at 1m <5mrem/h. The new patient-release 
criteria limits the total effective dose equivalent (TEDE) to 
<500mrem for the most exposed individual. The regulations 
of NRC expressed in a revision of Title 10, Part 35.75 [16] and 
in the Regulatory Guide 8.39 [16], state that RAI can be used 
with a TEDE limit of 5mSv as a default value for 131I activity, 
1,221MBq, or with exposure rate at 1m of 7mrem/h, or by es-
timating the patient-specific dose.
We released our patients if the dose rate fell below 10μSv/
h (1.0mR/h) at a distance of 1m, and most of our cases met 
this release-criterion value after 3 days. Earlier discharge is 
most welcome.
The limitations of this study are: a) the relatively small 
number of cases and b) the absence of behavioral factors 
like the number of baths the patient is taking, that may have 
an impact on the obtained parameters.
In conclusion, it is the opinion of the authors that after 
measuring the exposure rates most treated, DTC patients 
could be discharged after only one day of hospitalization, 
even patients that had received high doses of 131I (7.4GBq). It 
also demonstrates that patients who received high doses of 
131I, could be released based on the individual patient expo-
sure rate measurement.
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